Clinical Trial Update: A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers [Phase 3]

View source ↗

Summary

Phase 3 study of an unadjuvanted RSV maternal vaccine in high-risk pregnant women and infants born to vaccinated mothers was terminated; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• RSV maternal vaccine (unadjuvanted)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: TERMINATED | Results posted: 2024-02-06